{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:42:52Z","timestamp":1790095372774,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CUP H53D23007980001"],"award-info":[{"award-number":["CUP H53D23007980001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["1384"],"award-info":[{"award-number":["1384"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Inorganic Biochemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jinorgbio.2025.112916","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:31:07Z","timestamp":1744284667000},"page":"112916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases"],"prefix":"10.1016","volume":"270","author":[{"given":"Alessandra","family":"Barbanente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Cosola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Niso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"D'Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Indelicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Pacifico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Terenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinorgbio.2025.112916_bb0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4103\/0971-5916.198664","article-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","volume":"144","author":"Goswami","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","article-title":"Osteoclasts: what do they do and how do they do it?","volume":"170","author":"Teitelbaum","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/PL00021279","article-title":"The biology of multiple myeloma","volume":"126","author":"Drach","year":"2000","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF01605928","article-title":"Morphological typing of chondrosarcoma: a study of 94 cases","volume":"418","author":"Welkerling","year":"1991","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0035","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3390\/curroncol28050290","article-title":"Current overview of treatment for metastatic bone disease","volume":"28","author":"Tsukamoto","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016022","article-title":"Survival after bone metastasis by primary cancer type: a Danish population-based cohort study","volume":"7","author":"Svensson","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ccr.2017.04.013","article-title":"Cytotoxic platinum coordination compounds. DNA binding agents","volume":"351","author":"Brabec","year":"2017","journal-title":"Coord. Chem. Rev"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152007779314044","article-title":"Biochemical mechanisms of cisplatin cytotoxicity","volume":"7","author":"Cepeda","year":"2007","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0060","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1039\/C2CS35259A","article-title":"Targeting and delivery of platinum-based anticancer drugs","volume":"42","author":"Wang","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0070","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.2174\/092986709789760661","article-title":"The drug targeting and delivery approach applied to Pt-antitumour complexes. A coordination point of view","volume":"16","author":"Gabano","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0075","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1021\/ic00226a004","article-title":"Multinuclear NMR study of reactions of methylphosphonic acid, CH3PO3H2, and (aminoalkyl)phosphonic acids, NH2(CH2)NPO3H2 (n = 1-3), with the cis-diamminediaquaplatinum(II) cation and cis-diamminedihydroxoplatinum(II)","volume":"25","author":"Appleton","year":"1986","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0080","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1021\/jm0308040","article-title":"Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-bis(phosphonomethyl)glycine ligand","volume":"46","author":"Galanski","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0085","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1039\/b922222g","article-title":"Platinum(II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity","volume":"46","author":"Xue","year":"2010","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1248\/cpb.59.710","article-title":"Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor","volume":"59","author":"Nakatake","year":"2011","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0095","article-title":"Bone tumor\u2013targeted delivery of theranostic 195mPt-bisphosphonate complexes promotes killing of metastatic tumor cells","volume":"9","author":"Nadar","year":"2021","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0100","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/s41598-020-62039-2","article-title":"Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity","volume":"10","author":"Nadar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0105","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1039\/c2dt30712j","article-title":"Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs","volume":"41","author":"Piccinonna","year":"2012","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jinorgbio.2012.06.004","article-title":"Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum-bisphosphonate complexes in the treatment of bone tumors: a mini-review","volume":"117","author":"Iafisco","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0115","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1021\/jm3006838","article-title":"Revisiting [PtCl\u2082(Cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer","volume":"55","author":"Margiotta","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0120","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bcp.2009.09.019","article-title":"Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand","volume":"79","author":"Kasparkova","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0125","doi-asserted-by":"crossref","first-page":"15439","DOI":"10.1002\/chem.201202117","article-title":"Thermodynamic and mechanistic insights into translesion DNA synthesis catalyzed by Y-family DNA polymerase across a bulky double-base lesion of an antitumor platinum drug","volume":"18","author":"Brabec","year":"2012","journal-title":"Chem. \u2013 A Eur. J."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0130","doi-asserted-by":"crossref","first-page":"10904","DOI":"10.1039\/b919721d","article-title":"Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours","author":"Margiotta","year":"2009","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0135","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/acs.inorgchem.7b03261","article-title":"A potential bone-targeting hypotoxic platinum(II) complex with an unusual cytostatic mechanism toward osteosarcoma cells","volume":"57","author":"Zhang","year":"2018","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13569-016-0046-2","article-title":"Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients","volume":"6","author":"Conry","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0145","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2017","journal-title":"Eur. J. Cancer Care (Engl)"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1476-5810.2003.00026.x","article-title":"The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro","volume":"1","author":"Poirier","year":"2003","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02983531","article-title":"Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines","volume":"79","author":"Kimura","year":"2004","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/bcr412","article-title":"The role of bisphosphonates in breast cancer: direct effects of bisphosphonates on breast cancer cells","volume":"4","author":"Senaratne","year":"2001","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0165","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0170","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bone.2014.03.005","article-title":"Pleiotropic effects of bisphosphonates on osteosarcoma","volume":"63","author":"Ohba","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3892\/ol.2012.723","article-title":"Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells","volume":"4","author":"Chang","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0180","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1471-2474-12-146","article-title":"Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro","volume":"12","author":"Fu","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0185","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates MTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0190","first-page":"2713","article-title":"Combined effects of bisphosphonate and radiation on osteosarcoma cells","volume":"30","author":"Ryu","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.25051","article-title":"Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model","volume":"127","author":"Labrinidis","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0200","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with Ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0220","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jbmr.2182","article-title":"Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL","volume":"29","author":"Ohba","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0225","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0230","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4161\/cbt.10.6.12611","article-title":"Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial","volume":"10","author":"Facchini","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0235","doi-asserted-by":"crossref","DOI":"10.1039\/D3DT00734K","article-title":"Cisplatin and zoledronic acid: two drugs combined in a Pt(II) complex with potential antitumor activity towards bone tumors and metastases","volume":"52","author":"Barbanente","year":"2023","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0240","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1039\/C6DT01414C","article-title":"Platinum(IV) anticancer prodrugs - hypotheses and facts","volume":"45","author":"Gibson","year":"2016","journal-title":"Dalt. Trans."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0245","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/cmdc.201400061","article-title":"Trans, cis, cis-bis(benzoato)dichlorido(cyclohexane-1 R,2 R -diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer","volume":"9","author":"Gandin","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jinorgbio.2015.11.028","article-title":"Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands","volume":"160","author":"Margiotta","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0255","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/ic302100x","article-title":"NMR investigation of the spontaneous thermal- and\/or photoinduced reduction of trans dihydroxido Pt(IV) derivatives","volume":"52","author":"Petruzzella","year":"2013","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0260","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.3390\/ijms23137081","article-title":"Improvement of kiteplatin efficacy by a benzoato Pt(IV) prodrug suitable for oral administration","volume":"23","author":"Barbanente","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0265","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1039\/C6DT01976E","article-title":"Hydroxyapatite nanocrystals as a smart, PH sensitive, delivery system for kiteplatin","volume":"45","author":"Lelli","year":"2016","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0270","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41580-020-0236-x","article-title":"The regulation and functions of DNA and RNA G-quadruplexes","volume":"21","author":"Varshney","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0275","article-title":"875. The electrolyte type of ionized complexes","volume":"4587","author":"Feltham","year":"1964","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0280","first-page":"193","article-title":"A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]","volume":"8","author":"SC., D","year":"1970","journal-title":"Indian J. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0285","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1021\/ic702202x","article-title":"Conformer distribution in (cis \u22121,4-DACH)Bis(guanosine-5\u2032-phosphate)platinum(II) adducts: a reliable model for DNA adducts of antitumoral cisplatin","volume":"47","author":"Ranaldo","year":"2008","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0290","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1093\/nar\/gks152","article-title":"Interaction of human telomeric DNA with N- methyl mesoporphyrin IX","volume":"40","author":"Nicoludis","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0295","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s43440-023-00531-y","article-title":"Cytotoxic pathways activated by multifunctional thiosemicarbazones targeting sigma-2 receptors in breast and lung carcinoma cells","volume":"75","author":"Kopecka","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0300","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/ic00226a005","article-title":"NMR spectra of iminobis(methylenephosphonic acid), HN(CH2PO3H2)2, and related ligands and of their complexes with platinum(II)","volume":"25","author":"Appleton","year":"1986","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0305","article-title":"Bisphosphonate complexation and calcium doping in silica xerogels as a combined strategy for local and controlled release of active platinum antitumor compounds","volume":"3131","author":"Margiotta","year":"2007","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0310","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.jinorgbio.2008.07.008","article-title":"A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues","volume":"102","author":"Margiotta","year":"2008","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0315","doi-asserted-by":"crossref","first-page":"8385","DOI":"10.1039\/b914379c","article-title":"Smart delivery of antitumoral platinum complexes from biomimetic hydroxyapatite nanocrystals","volume":"19","author":"Iafisco","year":"2009","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0320","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.poly.2013.10.003","article-title":"The crystal structure of oxaliplatin: a case of overlooked pseudo symmetry","volume":"67","author":"Johnstone","year":"2014","journal-title":"Polyhedron"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26113417","article-title":"New oxaliplatin-pyrophosphato analogs with improved in vitro cytotoxicity","volume":"26","author":"Barbanente","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0330","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1021\/acsomega.6b00044","article-title":"Folding kinetics of single human telomeric G-quadruplex affected by cisplatin","volume":"1","author":"Ju","year":"2016","journal-title":"ACS Omega"},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2023.115149","article-title":"Electrochemical detection of oxaliplatin induced DNA damage in G-quadruplex structures","volume":"671","author":"Osmano\u011fullar\u0131","year":"2023","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0340","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jinorgbio.2006.11.005","article-title":"GG sequence of DNA and the human telomeric sequence react with cis-diammine-diaquaplatinum at comparable rates","volume":"101","author":"Ourliac Garnier","year":"2007","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35655-2","article-title":"Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis","volume":"8","author":"Alonso-de Castro","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0301-4622(90)80003-P","article-title":"Biophysical studies of the modification of DNA by antitumour platinum coordination complexes","volume":"35","author":"Brabec","year":"1990","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0355","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/nar\/gkg259","article-title":"Platinum cross-linking of adenines and guanines on the quadruplex structures of the AG3(T2AG3)3 and (T2AG3)4 human telomere sequences in Na+ and K+ solutions","volume":"31","author":"Redon","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jinorgbio.2025.112916_bb0360","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1021\/bi001565a","article-title":"Platination of the (T 2 G 4 ) 4 telomeric sequence: a structural and cross-linking study","volume":"40","author":"Redon","year":"2001","journal-title":"Biochemistry"}],"container-title":["Journal of Inorganic Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013425000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013425000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:30:06Z","timestamp":1762248606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0162013425000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":72,"alternative-id":["S0162013425000960"],"URL":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2025.112916","relation":{},"ISSN":["0162-0134"],"issn-type":[{"value":"0162-0134","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New oxaliplatin-zoledronate derivatives with potential antitumor activity towards bone tumors and metastases","name":"articletitle","label":"Article Title"},{"value":"Journal of Inorganic Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2025.112916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112916"}}